Long-term Study of AIR001 in Subjects With WHO Group 1 Pulmonary Arterial Hypertension Who Completed AIR001-CS05

PHASE2TerminatedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

March 31, 2013

Primary Completion Date

April 30, 2014

Study Completion Date

April 30, 2014

Conditions
Pulmonary Arterial Hypertension
Interventions
DRUG

AIR001

All doses specified are the amount loaded into the I-neb AAD System nebulizer.

Trial Locations (25)

1083

Gottsegen Gyorgy Hungarian, Budapest

1125

Semmelweis University, Budapest

2010

St. Vincent's Hospital, Darlinghurst

3004

The Alfred Hospital, Melbourne

4012

University of Debrecen, Debrecen

4032

The Prince Charles Hospital, Chermside

6720

University of Szeged, Szeged

7000

Royal Hobart Hospital, Hobart

15213

University of Pittsburgh Medical Center, Pittsburgh

21201

University of Maryland Medical Center, Baltimore

22042

Inova Fairfax Hospital, Falls Church

27710

Duke University Medical Center, Durham

40202

Kentuckiana Pulmonary Associates, Louisville

43210

The Ohio State University Medical Center, Columbus

45267

University of Cincinnati, Cincinnati

53215

Aurora St. Luke's Medical Center, Milwaukee

75390

University of Texas Southwestern Medical Center, Dallas

77030

Adaani Frost, M.D., Houston

80045

University of Colorado Denver, Aurora

90509

UCLA Medical Center, Torrance

92037

UCSD Medical Center, La Jolla

02111

Tufts Medical Center, Boston

02115

Brigham and Women's Hospital, Boston

02118

Boston University School of Medicine, Boston

63110-1093

Washington University School of Medicine, St Louis

Sponsors
All Listed Sponsors
lead

Aires Pharmaceuticals, Inc.

INDUSTRY